1Q EARNINGS: Merck looks to innovation not consolidation
This article was originally published in Scrip
Merck & Co pharmaceutical sales fell 5% during the first quarter of 2014 to $8.5bn versus $8.9bn a year ago due to generic competition and foreign exchange impacts, so Merck chairman and CEO Kenneth Frazier maintained his position that the company will focus on innovation in key therapeutic areas to drive value going forward.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.